{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:49:13Z","timestamp":1771652953161,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.cgh.2017.11.003","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T15:17:41Z","timestamp":1510154261000},"page":"186-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient"],"prefix":"10.1016","volume":"16","author":[{"given":"Michael P.","family":"Manns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmar","family":"Jaeckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.11.003_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.11.003_bib2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.11.003_bib3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/hep.23924","article-title":"Application of the 2010 American Association for the Study of Liver Diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis","volume":"52","author":"Muratori","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.11.003_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.11.003_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","article-title":"Oral budesonide for treatment of autoimmune chronic active hepatitis","volume":"8","author":"Danielsson","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.11.003_bib6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.11.003_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cgh.2017.11.003_bib8","first-page":"611","article-title":"Autoimmune hepatitis in southern Israel: a 15-year multicenter study","volume":"14","author":"Delgado","year":"2013","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.cgh.2017.11.003_bib9","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v12.i9.1362","article-title":"Budesonide induces complete remission in autoimmune hepatitis","volume":"12","author":"Csepregi","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.11.003_bib10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","article-title":"Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis","volume":"119","author":"Czaja","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.11.003_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1155\/2008\/509459","article-title":"The use of budesonide in the treatment of autoimmune hepatitis in Canada","volume":"22","author":"Zandieh","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.11.003_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1665-2681(19)31500-5","article-title":"Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis","volume":"11","author":"Mederacke","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cgh.2017.11.003_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.11.003_bib14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cgh.2016.12.040","article-title":"Efficacy and limitations\u00a0of budesonide as a second-line treatment for patients with autoimmune hepatitis","volume":"16","author":"Peiseler","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.11.003_bib15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/14656566.2014.931938","article-title":"Current and prospective pharmacotherapy for autoimmune hepatitis","volume":"15","author":"Czaja","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cgh.2017.11.003_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181107","article-title":"Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy","volume":"12","author":"Diestelhorst","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.cgh.2017.11.003_bib17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","article-title":"Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies","volume":"61","author":"Taubert","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.11.003_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.28517","article-title":"Human intrahepatic Tregs are functional, require IL-2 from effector cells for survival and are susceptible to fas ligand mediated apoptosis","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.11.003_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cgh.2017.11.003_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.autrev.2011.09.006","article-title":"Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome","volume":"11","author":"Efe","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cgh.2017.11.003_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","article-title":"Budesonide in previously untreated autoimmune hepatitis","volume":"25","author":"Wiegand","year":"2005","journal-title":"Liver Int"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517313149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517313149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:23:41Z","timestamp":1761542621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517313149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1542356517313149"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.11.003","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute","name":"copyright","label":"Copyright"}]}}